HIF-1 Activation Induces Doxorubicin Resistance in MCF7 3-D Spheroids Via P-glycoprotein Expression: a Potential Model of the Chemo-resistance of Invasive Micropapillary Carcinoma of the Breast
Overview
Authors
Affiliations
Background: Invasive micropapillary carcinoma (IMPC) of the breast is a distinct and aggressive variant of luminal type B breast cancer that does not respond to neoadjuvant chemotherapy. It is characterized by small pseudopapillary clusters of cancer cells with inverted cell polarity. To investigate whether hypoxia-inducible factor-1 (HIF-1) activation may be related to the drug resistance described in this tumor, we used MCF7 cancer cells cultured as 3-D spheroids, which morphologically simulate IMPC cell clusters.
Methods: HIF-1 activation was measured by EMSA and ELISA in MCF7 3-D spheroids and MCF7 monolayers. Binding of HIF-1α to MDR-1 gene promoter and modulation of P-glycoprotein (Pgp) expression was evaluated by ChIP assay and FACS analysis, respectively. Intracellular doxorubicin retention was measured by spectrofluorimetric assay and drug cytotoxicity by annexin V-FITC measurement and caspase activity assay.
Results: In MCF7 3-D spheroids HIF-1 was activated and recruited to participate to the transcriptional activity of MDR-1 gene, coding for Pgp. In addition, Pgp expression on the surface of cells obtained from 3-D spheroids was increased. MCF7 3-D spheroids accumulate less doxorubicin and are less sensitive to its cytotoxic effects than MCF7 cells cultured as monolayer. Finally, HIF-1α inhibition either by incubating cells with 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole (a widely used HIF-1α inhibitor) or by transfecting cells with specific siRNA for HIF-1α significantly decreased the expression of Pgp on the surface of cells and increased the intracellular doxorubicin accumulation in MCF7 3-D spheroids.
Conclusions: MCF7 breast cancer cells cultured as 3-D spheroids are resistant to doxorubicin and this resistance is associated with an increased Pgp expression in the plasma membrane via activation of HIF-1. The same mechanism may be suggested for IMPC drug resistance.
Mallya D, Gadre M, Varadharajan S, Vasanthan K Front Bioeng Biotechnol. 2025; 13:1457872.
PMID: 40028291 PMC: 11868281. DOI: 10.3389/fbioe.2025.1457872.
Singh V, Singh R, Goswami P, Manna P, Basu Baul T, Mandal A Sci Rep. 2025; 15(1):5302.
PMID: 39939702 PMC: 11821849. DOI: 10.1038/s41598-025-89761-z.
Omega-3 fatty acids: molecular weapons against chemoresistance in breast cancer.
Marchio V, Augimeri G, Morelli C, Vivacqua A, Giordano C, Catalano S Cell Mol Biol Lett. 2025; 30(1):11.
PMID: 39863855 PMC: 11762563. DOI: 10.1186/s11658-025-00694-x.
Li S, Gao S, Qin L, Ding C, Qu J, Cui Y Cancer Sci. 2024; 116(2):308-321.
PMID: 39568148 PMC: 11786311. DOI: 10.1111/cas.16396.
Esposito A, Ferraresi A, Vallino L, Garavaglia B, Dhanasekaran D, Isidoro C Int J Biol Sci. 2024; 20(13):5293-5311.
PMID: 39430243 PMC: 11488579. DOI: 10.7150/ijbs.96469.